Análise Descritiva dor artigo:

Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial

Harpreet Wasan MD a, Dr Angela M Meade DPhil b , Richard Adams MD c, Richard Wilson MD d, Cheryl Pugh BSc b, David Fisher MSc b, Benjamin Sydes b, Ayman Madi MD b, Bruce Sizer MB e, Charles Lowdell FRCP a, Gary Middleton MD f, Rachel ButlerBSc g, Prof Richard Kaplan MD b, Prof Tim Maughan MD h, on behalf of the COIN-B investigators

R3 Tamise da Silva Baptista


Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114.

Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370: 143-152.